Previous studies have suggested that pneumococcal choline binding protein A (PcpA) is important for the full virulence of Streptococcus pneumoniae, and its amino acid sequence suggests that it may play a role in cellular adherence. PcpA is under the control of a manganese-dependent regulator and is only expressed at low manganese concentrations, similar to those found in the blood and lungs. PcpA expression is repressed under high manganese concentrations, similar to those found in secretions. In this study, we have demonstrated that PcpA elicits statistically significant protection in murine models of pneumonia and sepsis. In the model of pneumonia with each of four challenge strains, statistically fewer S. pneumoniae cells were recovered from the lungs of mice immunized with PcpA and alum versus mice immunized with alum only. The immunizations reduced the median CFU by 4-to 400-fold (average of 28-fold). In the model of sepsis using strain TIGR4, PcpA expression resulted in shorter times to become moribund and subcutaneous immunization with PcpA increased survival times of mice infected with wild-type PcpA-expressing pneumococci.
Streptococcus pneumoniae is a gram-positive facultative anaerobe that is a major cause of morbidity and mortality worldwide. It is often the cause of bacterial pneumonia, otitis media, meningitis, and septicemia. The people at the highest risk of developing pneumococcal pneumonia are those with weakened or compromised immune systems, such as the elderly, infants, cancer patients, AIDS patients, and postoperative patients (13, 14, 38, 60) . S. pneumoniae is estimated to cause more than 1 million deaths in children each year worldwide (38) .
Although advances in drug therapies and vaccines have brought about a significant reduction in the incidence of pneumococcal disease, S. pneumoniae continues to be a threat to its target population (12, 13, 33) . A 7-valent polysaccharide-protein conjugate vaccine is currently being used in children. This vaccine contains the seven most common capsular serotypes associated with pneumococcal disease in children in the United States. In children, the vaccine is highly immunogenic and effective against invasive disease, but it is less effective against otitis media. Unfortunately, the 7-valent polysaccharide-protein conjugate vaccine is too expensive for use in most developing countries, where most of the pneumococcal deaths occur.
Of even greater concern, however, is the increased incidence of colonization and disease caused by non-vaccine-type pneumococci (3, 54, 57) , which had been predicted by prior studies using mathematical models (29, 30) . It has been observed that in a Native American population in Alaska, the continued use of the 7-valent vaccine has resulted in almost complete replacement disease caused by vaccine types not present in the 7-valent vaccine (54) . Continued increases in the magnitude of this serotype shift could result in a major reduction in the effectiveness of the 7-valent conjugate vaccine worldwide (22) .
In addition to the concern about serotype shift, attention should be given to the effect that a reduction in nasopharyngeal colonization with S. pneumoniae could have on other pathogens that colonize the nasopharynx. It has also been reported that colonization with Staphylococcus aureus of healthy children is inversely correlated with colonization with vaccine-type S. pneumoniae (3, 31, 44, 57) . This negative correlation is not seen between S. aureus and non-vaccine-type S. pneumoniae. These observations have been interpreted to suggest a direct competition between colonization with vaccine-type pneumococci and S. aureus, which could explain the increased incidence of S. aureus colonization after vaccination with the 7-valent conjugate vaccine.
If the above findings illustrating competition in colonization between pneumococci and S. aureus are supported by additional studies of colonization and disease with S. aureus, then it may be important to develop a pneumococcal vaccine antigen that will confer protection against invasive disease but not against pneumococcal colonization. Although such a vaccine would not be expected to elicit herd immunity against pneumococci, it should have the added advantage of not selecting for variant pneumococci that lack the vaccine antigen being used for immunization.
Pneumococcal choline-binding protein A (PcpA) (20, 50 ) is a potential vaccine candidate which is unlikely to elicit protection against colonization. PcpA is transcribed as a 2.3-kb monocistronic transcript encoding a putative 79-kDa protein containing a C-terminal choline-binding domain. PcpA is quite distinct, however, from a similarly named pneumococcal choline-binding protein referred to as both PspC and CbpA (11) . PcpA contains several leucine-rich repeats (LRRs) in its Nterminal half (50) . The protein is under the control of the manganese-dependent regulator psaR. RNA slot-blot analysis has revealed that an in vitro manganese concentration of 50 M resulted in repression of pcpA expression and that a con-centration of 0.1 M or lower resulted in full expression of pcpA (25) . PcpA mutants were identified as having reduced virulence in murine models of sepsis and pneumonia in a large-scale signature-tagged mutagenesis study in which mutants were forced to compete with wild-type bacteria during infections. In that study, mice were infected with serotype 4 S. pneumoniae by aspiration into the lungs (pneumonia model) and intraperitoneal injection (sepsis model) (20) .
LRRs are present in over 2,000 proteins found in viruses, bacteria, archaea, and eukaryotes. These proteins have been shown to participate in a wide variety of biological functions, including plant and animal immune responses, apoptosis, cell adhesion, signal transduction, DNA repair, DNA recombination and transcription, and RNA processing (4, 27) . The variable lymphocyte receptors of agnathans (jawless fish) are assembled through the recombination of LRR modular units (42) . Eukaryotic Toll-like receptors also employ LRR in their recognition of pathogen-associated molecular patterns (42, 43, 47) .
The LRR motif of LRR proteins participates in a common structural unit consisting of alpha helices and beta strands joined by loops, formed by the LRR units. This arrangement results in a "horseshoe-shaped" molecule, which provides a versatile scaffold for protein-protein interactions. There are several subfamilies of bacterial LRR proteins. PcpA is a member of the LRR Tp subfamily. This subfamily was originally identified in Treponema pallidum. Most of the proteins in this subfamily have been found associated with bacterial cell surfaces (24, 27, 45) . Most of the bacterial LRR Tp proteins that have been studied appear to play a role in surface adherence or aggregation (23, 24, 45, 52, 59 ).
Here we report the partial characterization of the S. pneumoniae LRR protein PcpA, the prevalence of the pcpA gene in strains of S. pneumoniae, the requirement for low manganese to permit PcpA expression in diverse pneumococci, the role that PcpA plays in the virulence of S. pneumoniae, and the protective effects of immunity to PcpA. Since PcpA is not required for colonization and is not expected to be expressed by pneumococci bathed in nasal mucosal secretions, immunity to it should not protect against colonization and, thus, may be able to protect against invasive disease without significantly enhancing the evolution of pneumococci to avoid the antiPcpA vaccine.
MATERIALS AND METHODS
Bacterial strains, medium, and growth conditions. S. pneumoniae strains TIGR4 and EF3030 and their derivatives were used in this study. Unless otherwise indicated, pneumococci were grown at 37°C in Todd-Hewitt broth with 0.5% yeast extract (THY) or on blood agar plates (Becton Dickinson, Sparks, MD). When appropriate, erythromycin was added to the medium at a concentration of 0.3 g/ml. Clinical isolates of S. pneumoniae (Table 1) and isolates of major clonal groups (Table 2) were used.
The clinical strains used in these studies were isolated within the last 25 years. Laboratory passage has been minimized by storing the bacteria in 10% glycerol and starting all new cultures from a scraping of the surface of the original vial. To examine the possible diversity of PcpA, isolates were selected from the group of strains utilized in the Streptococcus pneumonia Genome Diversity Project (http://genome.microbio.uab.edu/strep/info).
During strain construction, plasmids were maintained in Escherichia coli TOP10 cells (Invitrogen, Carlsbad, CA) grown in Luria-Bertani (LB) broth or on LB plates with 1.5% agar. Antibiotics were added to the growth medium: ampicillin (50 g/ml) for pCR2.1, pCR4, and pET-20b-based plasmids or erythromycin (400 g/ml) for pJY4164-based plasmids.
THY medium was used to grow S. pneumoniae in a high-manganese medium. For growth in low-manganese conditions, a manganese-depleted form of THY was prepared. THY medium was prepared according to the manufacturer's directions, with Chelex-100 (2% [wt/vol]) (Sigma Aldrich, St. Louis, MO) being added prior to autoclaving. After autoclaving, the THY-Chelex mixture was stirred overnight at room temperature and then filter sterilized. Prior to use, ZnCl 2 , MgCl 2 , CaCl 2 , and FeSO 4 were added at concentrations of 1 mM each, and MnSO 4 was added to a concentration of 0.1 M. Growth was monitored by monitoring optical density at 600 nm (OD 600 ).
Strain construction. The E. coli strains, plasmids, and primers used in this study are listed in Table 3 . Mutagenesis (37) was used to inactivate pcpA in the parental strains TIGR4 and EF3030. The construction of mutant strains was previously carried out as described in reference 25. A reverted mutant of the pcpA-inactivated form of EF3030 was created by transformation with chromosomal DNA isolated from the parent strain. Three backcrosses were performed before mutants were then selected for use in our murine models. Selection was done based on the loss of erythromycin resistance, conferred during the initial inactivation of pcpA.
rPcpA expression and purification. Recombinant PcpA (rPcpA) was expressed and purified as follows. The strains, plasmids, and primers used in this study are listed in Table 3 . Primers DTG-16 and DTG-12 were designed to amplify a 1,126-bp fragment of pcpA in strain TIGR4. The primers contain engineered restriction endonuclease sites BamHI and XhoI, respectively. This fragment was cloned into pCR4 with the TOPO TA cloning kit (Invitrogen). Purified plasmids were screened by endonuclease digestion with BamHI and XhoI (Promega, Madison, WI). Agarose gel electrophoresis, PCR analysis, and DNA sequencing were all used to confirm insertion of the pcpA fragment in the resulting plasmid, pDG-1. The insert from pDG-1 was subcloned into the pET20b expression vector (Novagen, San Diego, CA). The resulting plasmid, pJM-1, was transformed into the E. coli strain Rosetta (DE3)pLysS (Novagen).
Upon IPTG (isopropyl-␤-D-thiogalactopyranoside) induction, a truncated protein containing amino acids 19 to 391 was expressed. The overexpressed truncated protein was purified using the Novagen His-Bind purification kit, making use of a C-terminal histidine tag to facilitate purification. Subsequent sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis with Coomassie blue staining yielded a single band of approximately 41 kDa.
Production of polyclonal antibody to PcpA. Purified rPcpA was used to immunize a New Zealand White rabbit (Myrtle's Rabbity, Thompson Station, TN) to obtain anti-PcpA polyclonal serum. The rabbit was injected subcutaneously with 100 g of rPcpA in 2 ml of Freund's complete adjuvant. A second boost, with 100 g of rPcpA in Freund's incomplete adjuvant, was given 2 weeks later, and a third boost of 100 g of PcpA in Freund's incomplete adjuvant was given 2 weeks after the second boost. Two weeks following the final boost, the rabbit was bled by cardiac puncture, under anesthesia. The blood was allowed to clot, and serum was obtained by centrifugation and stored at Ϫ80°C.
PCR confirmation of pcpA in S. pneumoniae strains. The presence or absence of pcpA in various S. pneumoniae strains was checked using PCR primer pair BGP-1 and BGP-2. The primer pair was designed to amplify a 1,416-bp N- a Strain R6 was derived from strain D39, which was a patient isolate isolated in the 1920s. The other strains were clinical strains that are not separated by more than 10 passages from the original patient isolate.
terminal fragment of pcpA in strain TIGR4. The PCR products were then separated on a 0.8% Tris-acetate-buffered agarose gel, stained with ethidium bromide, and examined to determine their size.
S. pneumoniae cell fractionation. Protoplasts were produced by the method described by Yother and White (63), with slight modification. Log-phase cells, grown in low-manganese medium, were pelleted and washed in phosphatebuffered saline (PBS). The cells were then resuspended in 0.5 ml of 2% choline chloride, and the tube was inverted several times. The cells were then pelleted, and the supernatant was drawn off and stored at Ϫ20°C (choline elution fraction). Cells were pelleted again and washed once with 300 l of protoplast buffer (20% sucrose, 5 mM Tris [pH 7.4], 2.5 mM MgSO 4 ). The pellets were then resuspended in 1 ml of protoplast buffer. Mutanolysin (Sigma Aldrich, St. Louis, MO) was then added at 5 U per ml of culture pelleted. The suspended pellets were incubated overnight at room temperature. Cells were pelleted by centrifugation at 6,000 rpm for 10 min, and the supernatants were stored at Ϫ20°C (cell wall fraction). The protoplasts were then washed in 1 ml of protoplast buffer. The formation of protoplasts was confirmed by microscopic examination. The protoplasts were pelleted and lysed in 0.3 to 1 ml of distilled water and stored at Ϫ20°C (cell membrane/cytosolic fraction). Samples of each fraction were examined for the presence of PcpA by Western blot analysis.
Staining on S. pneumoniae. Mid-log-phase cells (OD 600 of 0.6), grown in highor low-manganese medium, were pelleted, washed with PBS, resuspended in PBS with 1% bovine serum albumin (PBSB), and incubated at room temperature for 20 min. Cells were pelleted and resuspended in PBSB or anti-PcpA serum diluted 1:100 in PBSB and incubated at 37°C for 30 min. (60) . Lowercase letters in the primer sequences denote mismatches used to create restriction endonuclease sites. All sequences are expressed 5Ј to 3Ј.
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Western blotting. Bacterial cultures were grown in high-or low-manganese medium to mid-log phase (OD 600 of 0.6). Equivalent amounts of each strain were washed twice with PBS, resuspended in PBS with SDS-PAGE sample buffer, and boiled for 5 min. Samples and a prestained protein standard (Invitrogen) were loaded onto a NuPAGE 10% Bis-Tris gel (Invitrogen) and separated by electrophoresis in MES (morpholineethanesulfonic acid)-SDS running buffer (Invitrogen) in accordance with the manufacturer's instructions. The proteins were then transferred to a nitrocellulose membrane with the Trans-Blot SD semidry transfer cell (Bio-Rad, Hercules, CA). The blot was probed with anti-PcpA polyclonal antibody diluted 1:1,000 in PBSB. Goat anti-rabbit IgG (HϩL)-alkaline phosphatase and streptavidin-alkaline phosphatase (Southern Biotechnology Associates, Inc., Birmingham, AL) were used as the secondary antibody. Colorimetric detection was performed with Sigma Fast nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate (NBT-BCIP) tablets (Sigma Aldrich).
Parenteral immunization of mice. Six-to eight-week-old CBA/CaHNBtkxid/J (CBA/N) mice (Jackson Labs, Bar Harbor, ME) were initially injected subcutaneously with 10 g of rPcpA with 2 g of aluminum hydroxide as an adjuvant, in a 200-l total volume. The first boost of 10 g rPcpA with aluminum hydroxide was given 2 weeks later. A second boost containing 10 g rPcpA without aluminum hydroxide was given 2 weeks later. The mice were then allowed to rest 2 weeks before being challenged with S. pneumoniae. Mice were bled 24 h prior to infection.
Murine model of sepsis. The virulence of pneumococci was examined in a systemic model of infection previously described (16, 46) . Six-to eight-week-old CBA/N mice were injected intravenously with 300 bacteria diluted in lactated Ringer's solution. The mice were monitored for 21 days. When they became unresponsive to touch and their surface body temperature decreased to below 24°C (measured using the scanning Raytek MX2 thermometer; Raytek, Santa Cruz, CA), they were scored as moribund and the date and time were recorded. All moribund mice were euthanized with CO 2 narcosis.
Murine model of pneumonia. Lung infections were performed as previously described (1, 8, 55) . Six-to eight-week-old CBA/N mice were anesthetized lightly with Isoflurane (MinRAD, Buffalo, NY). Following anesthetization, suspensions of 40 l of lactated Ringer's solution containing 5 ϫ 10 6 bacteria were introduced into the nares of the mice to induce aspiration pneumonia. After 7 days, the mice were sacrificed. The nasal cavities of the sacrificed mice were washed with 50 l of lactated Ringer's, as previously described (62) . The nasal wash was serially diluted and plated onto blood agar with gentamicin (4 g/ml). The lungs were harvested and placed into 2 ml of lactated Ringer's solution in a stomacher bag, homogenized, serially diluted, and plated onto blood agar with gentamicin in serial threefold dilutions.
Murine model of nasopharyngeal colonization. Intranasal inoculations were performed as previously described (1, 62) . Six-to eight-week-old CBA/N mice were infected intranasally with 10 6 bacteria in 10 l of lactated Ringer's solution without anesthesia. Infected mice were sacrificed after 7 days, and their nasal cavities were washed with 50 l of Ringer's solution. The nasal washes were serially diluted and plated on blood agar with gentamicin. Visible counts from blood agar plates were determined after overnight incubation in candle jars at 37°C.
Statistical analysis. Statistically analysis was carried out using Instat (GraphPad Software, Inc., San Diego, CA). Comparisons between the control and experimental groups of the time until mice were moribund or of the numbers of recovered CFU were conducted using the Mann-Whitney two-sample rank test. P values of Ͻ0.05 were considered to be statistically significant.
RESULTS
pcpA is present in clinically relevant strains of S. pneumoniae. The presence of pcpA was detected by PCR, with primers (BGP1 and BGP2) spanning the LRR region of the pcpA (Table 3 ) (data not shown). Each of the 25 strains examined (Tables 1 and 2 ) yielded a roughly 1,500-bp fragment. Eleven of these strains (Table 1) were isolated from patients within the last 25 years and are representative of the capsular types covered by the 7-valent conjugate vaccine, and one strain, R6, is a rough mutant of capsular type 2 strain D39.
The remaining 13 strains are S. pneumoniae strains ( Table 2 ) that were collected as part of the Genome Diversity Project (http://genome.microbio.uab.edu/strep/info/), which includes strains chosen to span the breadth of diversity in S. pneumoniae. These 12 strains were selected to be highly divergent to each other based on multilocus sequence typing (MLST) data (17) . These strains also represent 12 different capsule types from different regions of the world. Four of the strains were from patients with serious invasive disease, five were from asymptomatic carriage, two strains had a disease/colonization status unknown, and one strain was from a worldwide antibiotic-resistant clone (48) .
To test for the expression of PcpA in all of the strains, they were grown in low-manganese medium (Յ0.1 M) (19, 25) . Total cellular protein samples were prepared from mid-logphase cells cultured in the low-manganese medium. All of the strains listed in Tables 1 and 2 were examined, but only those representing capsular types included in the 7-valent vaccine are depicted (Fig. 1) . Total cellular protein samples were separated by SDS-PAGE and transferred to nitrocellulose. The blot was probed with anti-PcpA polyclonal antiserum. The blot identified a single band in lanes 2, 7, 8, and 9 and what appeared to be doublets (suggesting partial degradation or possibly differential glycosylation of PcpA) in lanes 3, 4, 5, and 6 ( Fig. 1) . There was no band identified in the pcpA-inactivated mutant TIGR4 pcpA. The PcpA bands all migrate at approximately 62 kDa, but there was some slight variation in the size of the native proteins. Comparison of the amino acid sequences of available genomes shows variation in the number of choline-binding repeats, as well as other minor differences.
Total cellular protein samples for the same strains were also prepared from all 25 strains by growing them in a high-manganese medium, but no bands were identified with the antiPcpA antiserum (data not shown). The PCR analysis in combination with the Western blot data demonstrated that pcpA is present in all 25 of the S. pneumoniae strains listed in Tables 1  and 2 .
PcpA is present on S. pneumoniae grown under low-manganese conditions. Prior studies from our laboratory showed that, through the action of the regulator PsaR, manganese can repress the transcription of the pcpA gene (25) . The present study showed that the manganese concentration directly affected the presence of PcpA on the surface of S. pneumoniae and that surface PcpA was accessible to antibody even on encapsulated pneumococci.
Cell fractionation was performed to determine if PcpA was FIG. 1. Western blot analysis of the presence of PcpA under lowmanganese conditions. After bacteria were cultured in a low-manganese medium until mid-log phase, total cellular protein samples were prepared. Samples were separated by SDS-PAGE, transferred to nitrocellulose, and probed with an rPcpA polyclonal antiserum. Lane 1, TIGR4 pcpA (pcpA mutant); lane 2, TIGR4 psaR (pcpA constitutive mutant); lane 3, D1091B; lane 4, EF5668; lane 5, BG10752; lane 6, V175; lane 7, L82013; lane 8, BG12730; lane 9, TJ0893. When preimmune rabbit serum was used in place of immune rabbit sera, the PcpA bands were not detected (data not shown). When the same strains were cultured in Todd-Hewitt broth (high manganese) none of them produced detectable PcpA (data not shown). associated with the cell wall or cell membrane/cytosol of S. pneumoniae. Western blot analysis of these cellular fractions revealed that PcpA was present predominantly in the cell wall of S. pneumoniae grown in low-but not high-manganese medium (data not shown). A small fraction of the PcpA was found to be associated with the cell membrane/cytosol, probably representing PcpA that had yet to be exported to the surface of the bacteria.
In addition to the cell fractionation, log-phase cells from wild-type S. pneumoniae strain TIGR4 were grown in high-or low-manganese medium and then stained with anti-PcpA polyclonal antiserum followed by fluorescein isothiocyanate (FITC)-conjugated anti-rabbit Ig. The labeled bacteria were then examined by immunofluorescence microscopy. The antibodies to PcpA were able to stain the bacteria grown under low-manganese growth conditions but not those grown in high manganese concentrations (Fig. 2) .
These results showed that PcpA is present on the surface of wild-type S. pneumoniae cultured under low-manganese conditions in vitro and suggested that PcpA is probably expressed in bacteria infecting low-manganese sites inside the host, such as the lungs and blood. Whether PcpA is exposed well enough to facilitate necessary PcpA-ligand interactions between the bacterium and the host epithelium during infection is not known. Whether regulation of PcpA production by manganese is generalizable to most pneumococci is not yet established and may be controversial (21, 31) .
Immunization with rPcpA elicits antibody and provides protection against lung and systemic infection but does not significantly affect nasopharyngeal colonization. Prior to challenge with S. pneumoniae, the mice were immunized with rPcpA mixed with aluminum hydroxide or received aluminum hydroxide alone. Total Ig (HϩL) was quantified for both groups of mice by enzyme-linked immunosorbent assay (8) . The geometric mean (Ϯ standard error of the mean) level of antibody specific for PcpA in the serum of the immunized mice was 0.465 Ϯ 0.119 g/ml, versus a mean of 0.002 Ϯ 0.002 g/ml for mice receiving the adjuvant alone. This indicated that the immunization successfully elicited an immune response to rPcpA.
To determine if the immunization protected mice from pneumonia, the immunized and alum-only mice were lightly anesthetized and inoculated in the nares with 5 ϫ 10 6 CFU of strain EF3030. This procedure results in the development of a focal pneumonia without bacteremia (1, 8, 55) . Protection in this model can thus be associated with pneumonia per se and not with sepsis in general (1, 8) . At 7 days postinfection, all mice were sacrificed. Bacterial counts were determined from homogenized lung tissues and nasal washes. There were less than 1/100 as many pneumococci recovered from the lung homogenates of mice immunized with rPcpA compared with those receiving adjuvant alone (Fig. 3A) (P ϭ 0.002).
These results indicate that immunization with rPcpA is able to elicit protection against pulmonary infection with S. pneumoniae. There was no significant difference in the bacterial counts recovered from the nasal washes of mice immunized with rPcpA compared with those receiving adjuvant alone (Fig.  3B) . The failure of immunity to PcpA to affect numbers of pneumococci in the nasal wash was anticipated, both because we did not expect the pneumococci in the nasal wash to express PcpA and because subcutaneous immunization with protein antigens adsorbed to aluminum hydroxide and injected subcutaneously has not, to our knowledge, conferred protection against nasal colonization with S. pneumoniae (61) .
Next, we determined whether subcutaneous immunization with PcpA would confer protection against focal lung infection for other strains of S. pneumoniae (TJ0893, serotype 14; EF9303, serotype 23F; and L82016, serotype 6B). Once again, we found that subcutaneous immunization with rPcpA elicited significant protection against each strain compared with mice receiving immunizations of just the adjuvant alone (Fig. 4) . The largest protective effects of immunization were observed for strains EF3030 (Fig. 3A) and L82016X (Fig. 4B) , which caused the highest levels of infection in the nonimmune mice.
Expression of PcpA is not required for optimal nasal colonization. In previous studies, our lab used mutant pneumococci to show that during pneumonia in mice that the expression of PcpA is important for the presence of pneumococci in the lung but did not have an effect on the numbers of pneumococci washed from the noses of the same animals. Because of the importance of the question about whether PcpA is needed for normal colonization, we examined the effect of pcpA inactivation in a model of nasopharyngeal carriage in which the mice did not have concomitant pneumonia. Without prior anesthesia, mice were inoculated with 10 6 CFU of either strain EF3030 or its pcpA-inactivated mutant, EF3030 pcpA. At 7 days postinfection, the mice were sacrificed and nasal washes were collected and plated to detect pneumococci. No significant difference was found between the numbers of bacteria recovered from the nasal washes of mice inoculated with either EF3030 or EF3030 pcpA (Fig. 5) .
Restoration of PcpA expression in pcpA-inactivated pneumococci restores virulence in pneumonia but does not affect the level of pneumococci in colonization. In a previous study using wild-type and mutant pneumococci of strain EF3030, we were able to demonstrate that an absence of pcpA resulted in a decrease in the number of CFU recovered in a 7-day lung infection (25) . This mutation did not affect the numbers of CFU recovered from the nasal wash of the same mice (25) or the numbers of CFU recovered from mice in the nasal colonization model above (Fig. 5) .
Because of the possibility that the EF3030 strain carrying the pcpA mutation may have had additional mutations that caused the observed effect on virulence, we investigated this issue further. The wild-type pcpA gene was reinserted, replacing the EF3030 pcpA mutation. CFU in colonization and pneumonia models for the wild-type parent, the EF3030 pcpA mutant, and the repaired strain were then compared. In colonization, no significant difference was seen in the mean log 10 CFU recovered for wild-type, mutant, and pcpA-repaired strains of EF3030 (3.11, 3.04, and 3.29 log 10 CFU, respectively). In the pneumonia model, we observed that the repaired pcpA mutant completely recovered virulence and was not significantly different from the original parental strain when CFU were determined in the lung homogenates (4.12 and 4.13 geometric mean log CFU, respectively, for the repaired mutant and the wild-type strain). However, as expected (25) , there were significantly fewer (P Ͻ 0.05) bacteria recovered from the lungs of mice inoculated with the strain EF3030 pcpA mutant (2.72 log CFU).
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We have thus observed that neither the absence of an intact pcpA gene nor the presence of an immune response in the host elicited by immunization with rPcpA resulted in a reduction in the numbers of pneumococci that were recovered in the nasal washes of mice. These observations were consistent with the fact that the manganese concentration in the rat and human nasopharynx (Ͼ36 M) is high enough to suppress pcpA transcription (15, 26, 51, 58) . Under these conditions, pcpA tran- scription would be repressed by PsaR (25) in the nasopharynx. Thus, immunity to PcpA would be expected to have little effect on bacteria in this host site. However, the lack of an effect of subcutaneous immunization with PcpA on colonization would not, by itself, rule out the possibility that mucosal immunization may lead to protection, since intranasal immunization has been more effective than subcutaneous immunization using another pneumococcal antigen (61) .
PcpA and immunity to PcpA affect virulence in the murine model of systemic infection. To evaluate the ability of immunity to PcpA to protect against sepsis, CBA/N mice were first subcutaneously immunized with PcpA in aluminum hydroxide or with aluminum hydroxide alone as a control and then challenged with S. pneumoniae capsular type 4 strain TIGR4. This strain was used rather than EF3030 since TIGR4 can much more readily cause bacteremia and sepsis in mice (25, 49) . The immunized animals were challenged intravenously with 300 CFU of S. pneumoniae TIGR4. Survival was monitored for 21 days. Mice receiving rPcpA immunizations had a median time to become moribund that was extended by 43.5 h compared with mice receiving adjuvant alone (Fig. 6) . Twenty-six percent of mice immunized with rPcpA lived, while no mice immunized with aluminum hydroxide alone lived; this difference in survival rates was statistically significant (P ϭ 0.007).
Inactivation of pcpA reduces the virulence of pneumococci following intravenous inoculation. It was previously reported that inactivation of pcpA results in reduced virulence in the murine model of pneumonia (25) and in a lung-sepsis model (20) . In the present studies, the effect of pcpA inactivation on systemic infection following intravenous challenge was examined by infecting naive mice with 300 CFU of either TIGR4 or its pcpA-inactivated mutant, TIGR4 pcpA. The median time for mice infected with TIGR4 pcpA to become moribund was extended by 31.5 h (P ϭ 0.0299) compared with those infected with wild-type bacteria (Fig. 7) . This demonstrated that PcpA plays at least a small role in the ability of S. pneumoniae to cause systemic diseases. 
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DISCUSSION
The S. pneumoniae LRR protein PcpA was found to be an important virulence determinant in pneumococcal lung infections. PcpA also appears to play a role in sepsis. The original evidence that PcpA may be required for virulence came from Hava and Camilli, who used a genetic screen to identify genes in which mutations impacted the virulence of a highly invasive strain (20) when bacteria are aspirated into the lungs. Since they monitored the effects of the mutation on the numbers of CFU in the lungs of the infected mice (20) , their data suggest that pcpA could play a role in lung infection. The studies of Hava and Camilli used competition between mutant and wildtype pneumococci, which, for many genes, can be an extremely sensitive measure of relative virulence. On the other hand, it frequently magnifies the difference seen with pure cultures in vivo. We have confirmed the findings of Hava and Camilli with regard to the effect of PcpA on lung infection by using an aspiration pneumonia model that employs a challenge strain that causes focal pneumonia and does not invade the blood (25) . Our present and past (25) studies thus clearly demonstrate that PcpA is able to play an important role in the lungs. The prior studies of Hava and Camilli, however, did not determine whether or not immunization with rPcpA might be protective, nor did they examine the percentage of strains of S. pneumoniae that express the protein.
We demonstrated here that pcpA is expressed by each of the 25 diverse S. pneumoniae strains examined when they are grown under low-but not high-manganese conditions. In addition, we demonstrated that, under conditions of low manganese, PcpA is present on the surface of S. pneumoniae. The surface expression of PcpA is in accordance with the expression of other LRR proteins described in group A and group B streptococci. PcpA's potential for use as a vaccine antigen is supported by our observation that prior immunization with rPcpA resulted in the presence of 1/100 as many pneumococci in infected lungs. We also observed a statistically significant effect of immunization with PcpA on the protection against sepsis.
The failure of PcpA to be expressed at high manganese concentrations was consistent with the failure of pcpA mutants to affect colonization and thus strongly suggests that immunization with PcpA should not protect against colonization. Thus, taken together our data indicate that immunity to PcpA elicited by systemic immunization may be relatively specific for invasive disease. In two recent papers (21, 31) , results for pcpA expression appeared to be at variance with that reported previously in our lab (25) . Both studies examined capsular type 2 strain D39, which was originally isolated over 100 years ago and has been extensively passaged ever since, yielding many different sublines (28) . Although one of the studies examined two additional strains (31), pcpA expression was not the predominant focus of either study. Moreover, neither of the two studies took into account the need to control manganese levels (25) when examining pcpA expression. Any differences in results between the three studies will hopefully be resolved in future publications.
Although other antigens have been reported to elicit protection against pulmonary infection and sepsis (9, 11, 35, 56) , PcpA is the first antigen that may offer stronger protection against pneumonia than against sepsis. The ability of PcpA to protect against lung infection and sepsis but not colonization is similar to what has been observed with PdB (5, 39, 40) , a genetic toxoid of pneumolysin, which, like PcpA, fails to elicit protection against colonization (6) .
This "tissue site-specific" protection afforded by rPcpA may prove to be of value for vaccine development since it can elicit protection against lung infection without affecting the dynamics of nasopharyngeal colonization. Immunization of children with the 7-valent conjugate vaccine has reduced colonization and disease with the vaccine capsular serotypes, while there has been a replacement in colonization (3, 34, 54) as well as disease (22, 54) with capsular types not present in the vaccine.
A vaccine that protected against pneumonia without affecting colonization might avoid causing serotype replacement and increased replacement disease from organisms such as S. aureus. Since it is believed that most transmission of pneumococci is from colonized individuals, a vaccine antigen such as PcpA that did not prevent colonization might also avoid creating a selective pressure that could result in the evolution of mutant strains that could no longer be protected against by the vaccine.
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